IDEXX Laboratories Inc (IDXX)
Official siteHEALTHCARE • DIAGNOSTICS & RESEARCH • NASDAQ
Market Cap: $55.48B
Last updated: Nov 17, 2026 at 5:53 PM ET
IDEXX Laboratories Inc (IDXX) Statistics
IDEXX Laboratories (IDXX) has a market cap of $55.48B and an enterprise value of $56.13B. Its return on invested capital of 44.29% compares with a 6.88% median across 12 similar companies.
Total Valuation
Enterprise value is 1.17% above the market cap, as debt exceeds cash.
| Market Cap | $55.48B |
|---|---|
| Enterprise Value | $56.13B |
| Latest price (Nov 17, 2026) | $690.24 |
Key Dates
The next earnings report is expected on Feb 1, 2027, covering the quarter ending Dec 31, 2026.
| Next Earnings Date | Feb 1, 2027 (expected) |
|---|---|
| Last Earnings Date | Nov 2, 2026 |
| Fiscal Year End | December |
Valuation Ratios
Sales and book value multiples are 11.7x and 29.1x. Its year-end P/E ranged from 36.8x to 77.4x from 2016 to 2025.
| P/E Ratio | 46.6x |
|---|---|
| Forward P/E | 45.1x |
| P/S Ratio | 11.7x |
| Forward P/S | 11.7x |
| P/B Ratio | 29.1x |
| P/TBV Ratio | 49.0x |
| P/FCF Ratio | 41.7x |
| P/OCF Ratio | 39.1x |
| PEG Ratio | 3.6 |
Enterprise Valuation
Counting debt and cash, the company is valued at 33.1x EBITDA and 42.2x free cash flow.
| EV / Earnings | 47.5x |
|---|---|
| EV / Sales | 12.0x |
| EV / EBITDA | 33.1x |
| EV / EBIT | 37.3x |
| EV / FCF | 42.2x |
Price Statistics
The stock is up 0.04% over 52 weeks and trades 21.28% above its 50-day average.
| Beta (1Y) | 0.81 |
|---|---|
| 52-Week Change | +0.04% |
| 1-Month Change | +24.19% |
| 3-Month Change | +22.77% |
| 6-Month Change | +26.30% |
| 5-Year Change | -17.25% |
| 10-Year Change | +414.48% |
| Total Return (1Y) | +0.04% |
| Total Return (3Y CAGR) | +14.18% |
| Total Return (5Y CAGR) | +1.72% |
| Return vs SPY (1Y) | -8.57% |
| Max Drawdown (1Y) | -34.17% |
| Max Drawdown (3Y) | -37.41% |
| Sharpe Ratio (1Y) | 0.08 |
| Correlation with SPY (1Y) | 0.31 |
| 50-Day Average | $569.11 |
| 200-Day Average | $572.75 |
| 52-Week Range | $500.61 to $769.98 |
| RSI (14 Days) | 66.4 |
| Average Volume (20 Days) | 682.35K |
The 5 and 10 year changes compare month-end closes, adjusted for splits, through Oct 2026.
Financial Position
Current assets cover 1.19x current liabilities, and total debt is 0.45x shareholder equity.
| Current Ratio | 1.19x |
|---|---|
| Quick Ratio | 0.88x |
| Debt / Equity | 0.45x |
| Debt / EBITDA | 0.51x |
| Debt / FCF | 0.65x |
| Interest Coverage | 43.54x |
Returns and Efficiency
Return on invested capital is 44.29% over the last 12 months, against a 5-year average of 40.17%.
| Return on Equity (ROE) | 63.25% |
|---|---|
| Return on Assets (ROA) | 31.89% |
| Return on Invested Capital (ROIC) | 44.29% |
| Return on Capital Employed (ROCE) | 61.65% |
| ROE (5Y Average) | 79.62% |
| ROA (5Y Average) | 27.96% |
| ROIC (5Y Average) | 40.17% |
| Asset Turnover | 1.31x |
| Inventory Turnover | 4.44x |
| Receivables Turnover | 7.50x |
| Cash Conversion Cycle | 101 days |
Taxes
Income tax took 20.07% of pretax income over the last 12 months.
| Income Tax (TTM) | $296.78M |
|---|---|
| Effective Tax Rate | 20.07% |
Scores
IDXX has an Altman Z-Score of 23.20, in the safe zone above 2.99, and a Piotroski F-Score of 8 of 9, in the strong band of 8 or 9.
Altman Z-ScoreDistress below 1.81Safe above 2.99
Piotroski F-ScoreWeak at 2 or lessStrong at 8 or more
| Altman Z-Score | 23.20 |
|---|---|
| Altman Z Zone | Safe |
| Piotroski F-Score | 8 of 9 |
| Piotroski Strength | Strong |
Income Statement
Revenue of $4.66B over the last 12 months is up 11.87% from the 12 months before.
| Revenue | $4.66B |
|---|---|
| Revenue Growth (YoY) | +11.87% |
| Gross Profit | $2.92B |
| Operating Income | $1.51B |
| Pretax Income | $1.48B |
| Net Income | $1.18B |
| EBITDA | $1.66B |
| EBIT | $1.51B |
| Reported EPS (TTM) | $14.80 |
Trailing 12 months through Sep 30, 2026.
Balance Sheet
Shareholder equity funds 50.40% of the $3.71B in total assets.
| Cash and Equivalents | $197.54M |
|---|---|
| Total Debt | $848.88M |
| Net Debt | $651.34M |
| Net Debt Per Share | $8.26 |
| Working Capital | $235.78M |
| Shareholder Equity | $1.87B |
| Book Value Per Share | $23.71 |
| Tangible Book Value | $1.11B |
| Tangible Book Per Share | $14.09 |
| Total Assets | $3.71B |
| Total Liabilities | $1.84B |
Balance sheet as of Sep 30, 2026.
Cash Flow
After $114.99M of capital spending, operating cash flow left $1.30B of free cash flow.
| Operating Cash Flow | $1.42B |
|---|---|
| Capital Expenditures | $114.99M |
| Free Cash Flow | $1.30B |
| FCF Per Share | $16.55 |
| Depreciation and Amortization | $158.02M |
| Share Repurchases | $1.05B |
Trailing 12 months through Sep 30, 2026.
Margins
The operating margin is 32.30%, against a 5-year average of 29.24%.
| Gross Margin | 62.72% |
|---|---|
| Operating Margin | 32.30% |
| Pretax Margin | 31.72% |
| Net Margin | 25.36% |
| EBITDA Margin | 35.69% |
| EBIT Margin | 32.30% |
| FCF Margin | 27.97% |
| Gross Margin (5Y Average) | 60.19% |
| Operating Margin (5Y Average) | 29.24% |
| Net Margin (5Y Average) | 22.76% |
Growth
Revenue grew 8.52% a year over 3 years, and EPS 17.63% a year.
| Revenue Growth (3Y CAGR) | +8.52% |
|---|---|
| Revenue Growth (5Y CAGR) | +9.72% |
| EPS Growth (3Y CAGR) | +17.63% |
| EPS Growth (5Y CAGR) | +15.14% |
| FCF Growth (3Y CAGR) | +38.94% |
| FCF Growth (5Y CAGR) | +14.33% |
| Operating Income Growth (3Y CAGR) | +14.81% |
| Book Value Per Share Growth (2Y CAGR) | +6.07% |
| Tangible Book Per Share Growth (2Y CAGR) | +4.31% |
Dividends and Yields
IDXX does not pay a dividend. Its free cash flow yield is 2.40%.
| Earnings Yield | 2.15% |
|---|---|
| FCF Yield | 2.40% |
| Buyback Yield | 1.74% |
| Shareholder Yield | 1.74% |
Stock Splits
The last split was a 2-for-1 forward split on Jun 16, 2015.
| Last Split Date | Jun 16, 2015 |
|---|---|
| Split Type | Forward split |
| Split Ratio | 2:1 |
Peer Position
Against 11 similar companies, IDXX has the highest P/E.
P/E RatioPeer median 27.1x
P/S RatioPeer median 5.9x
ROICPeer median 6.88%
Revenue Growth (Trailing 4 Quarters, YoY)Peer median +6.27%
| P/E Ratio | 46.6x vs 27.1x median |
|---|---|
| P/S Ratio | 11.7x vs 5.9x median |
| ROIC | 44.29% vs 6.88% median |
| Revenue Growth (Trailing 4 Quarters, YoY) | +11.87% vs +6.27% median |
Analyst Forecast
Consensus estimates put revenue growth at 9.69% and EPS growth at 13.69% a year over the next 2 fiscal years.
| Revenue Growth Forecast (2Y CAGR) | +9.69% |
|---|---|
| EPS Growth Forecast (2Y CAGR) | +13.69% |
Price Target
Analyst price targets are part of paid GNG plans. See plans
GNG Valuation
| GNG view | Undervalued |
|---|
GNG fair value is part of GNG Pro. See plans
Frequently Asked Questions About IDXX
What is IDXX's market cap?
IDEXX Laboratories has a market cap of $55.48B. Its enterprise value, which adds debt and subtracts cash, is $56.13B.
What is IDXX's P/E ratio?
IDEXX Laboratories has a trailing P/E ratio of 46.6x and a forward P/E of 45.1x.
How many shares of IDXX are outstanding?
IDEXX Laboratories has 78.83M shares outstanding. The count is down 1.59% from a year earlier.
Does IDXX pay a dividend?
No. IDEXX Laboratories does not pay a dividend.
How much debt does IDXX have?
IDEXX Laboratories has $848.88M of total debt and $197.54M of cash and equivalents, a net debt position of $651.34M.
IDXX pages: Overview, Charting, Earnings, Forecast, Financials, Statistics, Valuation, Competitors, Government Contracts